Remarks

• These recommendations pertain only to South America.
• Quantitative or semi-quantitative determination of G6PD activity must be done before tafenoquine administration.
• Tafenoquine is not recommended in pregnant and lactating women.
• Tafenoquine is not recommended in patients receiving artemisinin-based combination therapies for the treatment of P. vivax.
• Controlled deployment and /or further research is encouraged outside of South America, to generate evidence of the efficacy and safety of tafenoquine compared to primaquine as an anti-relapse treatment.
• No data is available comparing tafenoquine with primaquine given at a total dose of 7.0 mg/kg

Practical info

• Quantitative or semi-quantitative G6PD testing MUST be done prior to tafenoquine administration.
• Dose: ◦ Adults, adolescents and children weighing more than 35 kg: the administration of a single 300 mg dose (two 150 mg tafenoquine tablets) is recommended on Day 1 or Day 2 of the 3-day course of chloroquine ◦ Children ≥ 2 years of age and weighing >10 kg to ≤ 35 kg: Dispersible tablet dose recommendations for children (>10 kg to ≤ 35 kg) Body weight (kg) Total dose Number of tablets > 10 to ≤ 20 100 mg Two 50 mg dispersible tablets > 20 to ≤ 35 200 mg Four 50mg dispersible tablets
• Tafenoquine is NOT recommended for pregnant or lactating women.